CN111718292B - 一种米力农中间体化合物 - Google Patents
一种米力农中间体化合物 Download PDFInfo
- Publication number
- CN111718292B CN111718292B CN201910213586.2A CN201910213586A CN111718292B CN 111718292 B CN111718292 B CN 111718292B CN 201910213586 A CN201910213586 A CN 201910213586A CN 111718292 B CN111718292 B CN 111718292B
- Authority
- CN
- China
- Prior art keywords
- milrinone
- reaction
- intermediate compound
- mol
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 229960003574 milrinone Drugs 0.000 title claims abstract description 117
- 150000001875 compounds Chemical class 0.000 title claims abstract description 83
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims description 110
- 238000003756 stirring Methods 0.000 claims description 61
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 26
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 19
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 claims description 17
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 9
- 239000007810 chemical reaction solvent Substances 0.000 claims description 9
- 239000003054 catalyst Substances 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000011261 inert gas Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004327 boric acid Substances 0.000 abstract description 2
- 238000013341 scale-up Methods 0.000 abstract description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 70
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 60
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 44
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 33
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
- 239000000706 filtrate Substances 0.000 description 33
- 238000002425 crystallisation Methods 0.000 description 29
- 230000008025 crystallization Effects 0.000 description 28
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 28
- 238000001914 filtration Methods 0.000 description 24
- 229910052786 argon Inorganic materials 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- 239000008213 purified water Substances 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 20
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- 239000013078 crystal Substances 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 238000000967 suction filtration Methods 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000001035 drying Methods 0.000 description 11
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 239000012295 chemical reaction liquid Substances 0.000 description 6
- ILRVKOYYFFNXDB-UHFFFAOYSA-N 1-pyridin-4-ylpropan-2-one Chemical compound CC(=O)CC1=CC=NC=C1 ILRVKOYYFFNXDB-UHFFFAOYSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960002105 amrinone Drugs 0.000 description 3
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- WBQTXTBONIWRGK-UHFFFAOYSA-N sodium;propan-2-olate Chemical compound [Na+].CC(C)[O-] WBQTXTBONIWRGK-UHFFFAOYSA-N 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- OEICGMPRFOJHKO-UHFFFAOYSA-N 2-(ethoxymethylidene)propanedinitrile Chemical compound CCOC=C(C#N)C#N OEICGMPRFOJHKO-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- YTEIHWVCQJZNEN-UHFFFAOYSA-N 3-pyridin-4-ylpyridine Chemical class C1=CN=CC(C=2C=CN=CC=2)=C1 YTEIHWVCQJZNEN-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- BDUXJBSAGHJZLY-UHFFFAOYSA-N ethyl pyridine-2-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1=CC=CC=N1 BDUXJBSAGHJZLY-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 102000010861 Type 3 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037543 Type 3 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- -1 and among them Chemical compound 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000005893 bromination reaction Methods 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 208000021264 digitalis poisoning Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XQUXKZZNEFRCAW-UHFFFAOYSA-N fenpropathrin Chemical compound CC1(C)C(C)(C)C1C(=O)OC(C#N)C1=CC=CC(OC=2C=CC=CC=2)=C1 XQUXKZZNEFRCAW-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
本发明提供了一种米力农中间体化合物,并公开了一种该米力农中间体化合物的制备方法,属于药物合成技术领域。本发明以α‑取代乙酰乙醛即SM‑1与4‑吡啶硼酸(烷)即SM‑2反应,得米力农中间体化合物Ⅰ。利用该米力农中间体化合物制备米力农产品操作简便,安全性高,收率高,适合工业化放大生产,所得高纯度的米力农成品,外观及纯度均达到标准。
Description
技术领域
本发明属于药物合成技术领域,具体涉及一种米力农中间体化合物。
背景技术
米力农(Milrinone),又名甲氰吡啶酮,其CAS号为:78415-72-2,系1,6-二氢-2-甲基-6-氧代-[3,4'-联吡啶]-5-甲腈的通用名称,最早由美国Sterling公司研制开发成功,1987年首次在美国被FDA批准,并于1992年在美国正式上市,随后在英国、法国、德国、荷兰、比利时和巴西等国家上市销售,临床上用其乳酸盐,主要适用于治疗顽固性心力衰竭和已发生洋地黄中毒的心力衰竭病人,新近研究显示米力农还可用于心外科体外循环后低心排综合征、解除搭桥血管痉挛、改善心脏原位移植病人心功能及抗炎症反应、改善内脏血流灌注等。其化学结构如下所示:
米力农系非洋地黄、非儿茶酚胺类强心药,是磷酸二酯酶抑制剂代表药,为氨力农(Amrinone)的同系药物,它能选择性地抑制心肌细胞内的磷酸二酯酶III(PDE III),改变细胞内外钙离子的转运,增强心肌收缩力,在治疗充血性心力衰竭(CHF)和扩张血管等方面正在发挥越来越重要的作用。其效力比氨力农强10~30倍,而无后者的血小板减少和低血压等不良反应。
目前报道的关于米力农的合成工艺主要有以下几类方法:
第一类方法是采用“直线式”合成路线(如US4469871A,US4413127A,EP0095152,US4313951A,J.Med.Chem.,1986,29,635-640,CN103288725B,CN104387320B,CN1253439C,CN106243032A,CN105777626A,CN104526975A,CN101143844A等):首先以4-甲基吡啶为起始原料,制备出1-(4-吡啶基)-2-丙酮,该步反应可以通过两条路径实现,第一条路径是在正丁基锂或苯基锂条件下与乙酸乙酯反应。第二条路径是4-甲基吡啶和乙酰氯在室温下反应16h。之后1-(4-吡啶基)-2-丙酮与原甲酸三烷基酯或N,N-二甲基甲酰胺二甲基缩醛(DMF-DMA)反应后再与α-氰基乙酰胺或丙二腈经“一锅煮”反应得到米力农粗品,再通过重结晶得到注射级的精品米力农。“直线式”合成路线,路线较长,1-(4-吡啶基)-2-丙酮的利用率较低,收率较低,导致其生产成本较高;在最后环化步骤中,所应用的丙二腈毒性较大。
第二类方法是采用“汇聚式”合成路线(如Heterocycles,Vol.23,NO.6,1985,1479-1482,CN103664773A等):该路线同样以4-甲基吡啶为起始原料,制备出1-(4-吡啶基)-2-丙酮,然后再以丙二腈和原甲酸三乙酯为原料制备出α-乙氧基亚甲基丙二腈,最后将1-(4-吡啶基)-2-丙酮和α-乙氧基亚甲基丙二腈反应制备出米力农粗品,通过重结晶得到精品米力农。此方法得到的粗品颜色发红,需要三次精制得到最终成品,总收率只有38%左右,与其他路线的70%的收率相比并无明显优势。
第三类方法则是专利CN105037261B公开的以丙酮与甲酸乙酯为起始物料,在碱性条件下缩合后,与α-氰基乙酰胺环合后经NBS溴代制得关键中间体,最后与1-吡啶硼酸进行Suzuki偶联反应合成米力农。该工艺在溴代反应中应用到毒性较大的二氯乙烷作为反应溶剂。此外,文献Adv.Synth.Catal.,2010,352,3255-3266公开了该方案通过一步直接偶联反应合成米力农反应性能较差的依据,作者则以苄基对羟基进行保护后再偶联,最后氢解脱苄基制得米力农成品,使得反应步骤延长,同样不适合工业化放大生产。
第四类方法是文献Heterocycles,Vol.31,NO.3,1990,523-527公开的一种以2-烷氧基-5-溴-6-甲基吡啶为原料,在正丁基锂的碱性条件下经碘化亚铜催化在-78℃与乙氧甲酰基吡啶盐酸盐反应后,再经空气氧化后制得3,4'-联吡啶衍生物,3,4'-联吡啶衍生物经氢解脱保护基,NBS溴代后,最后与氰化钾反应制得目标产品。该合成路线比较复杂,需要预先制备乙氧甲酰基吡啶盐酸盐,并且反应条件苛刻,需要在-78℃下进行,对设备要求较高,同时氰基的引入采用剧毒品氰化钾,使得工艺安全性较低,不适合工业化生产。
综上所述,在已经被报道的制备米力农的技术方法中,主要存在以下问题:
(1)现有的米力农合成方法所制备的米力农纯度不高,颜色发红,通过进一步精制手段也很难达到预定的效果。
(2)米力农的合成过程,普遍存在反应步骤较长,由此造成整体收率偏低。
(3)现有的米力农的合成路线比较复杂,反应条件苛刻,一些需要应用剧毒品氰化钾或丙二腈,使得该工艺操作安全性较低,工业化生产较难实现。
总结现有技术存在的较多问题,研究寻找一条反应条件温和,操作过程简便,产品收率高、纯度高,生产成本低的适合工业化生产米力农的制备方法仍是目前需要解决的问题。
发明内容
针对目前现有米力农制备技术存在的问题,本发明提供了一种米力农中间体化合物Ⅰ,并提供了该化合物的制备方法;该方法反应条件温和,操作过程简便,生产成本低;利用该化合物制备米力农具有较高的纯度、收率。
本发明的具体技术方案如下:
一种如式Ⅰ所示的米力农中间体化合物:
一种如式Ⅰ所示的米力农中间体化合物的制备方法,以SM-1与SM-2反应,得米力农中间体化合物Ⅰ,反应式如下:
其中,X为I、TfO、Br中的一种;R为OH、CH2CH3中的一种。
优选地,X为Br,R为OH。
一种米力农中间体化合物Ⅰ的制备方法,具体包括以下步骤:
惰性气体保护,室温条件下,将催化剂加入反应溶剂中,搅拌混匀后,向反应溶剂中加入碱的水溶液、化合物SM-1和化合物SM-2,搅拌控温反应,得米力农中间体化合物Ⅰ。
优选地,所述的催化剂为Pd(PPh3)4[四(三苯基膦)钯]、Pd(PPh3)2Cl2[双三苯基磷二氯化钯]、Pd(dppf)Cl2[[1,1'-双(二苯基膦基)二茂铁]二氯化钯]、Pd2(dba)3[三(二亚苄基丙酮)二钯]、Pd(OAc)2(PPh3)2[二(三苯基膦)二乙酸钯]中的一种或其组合,特别优选Pd(PPh3)4。
优选地,所述的反应溶剂为乙醇、异丙醇、乙腈、1,4-二氧六环、水、甲苯、N,N-二甲基甲酰胺、二甲基亚砜中的一种或其组合,其中特别优选二甲基亚砜。
优选地,所述的碱为K2CO3、Na2CO3、Cs2CO3、K3PO4、Na3PO4、NaOAc、KOAc中的一种或其组合,其中特别优选KOAc。
优选地,所述的化合物SM-1、化合物SM-2、碱、催化剂的投料摩尔比为1:1.05~1.3:2.6~4.5:0.03~0.07,其中特别优选1:1.2:3.4:0.05。
优选地,所述的化合物SM-1与反应溶剂质量体积比为1:10~15,g/mL。
优选地,所述的碱的水溶液摩尔浓度为6.0~7.0mol/L。
优选地,所述的控温反应为控温回流反应。
在一优选方案中,后处理步骤为控温反应结束后,过滤,将滤液加入纯化水中,萃取剂提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后即为米力农中间体化合物Ⅰ;优选地,所述的纯化水的体积为反应溶剂体积的3~5倍;优选地,所述的萃取剂为二氯甲烷、氯仿、乙酸乙酯、甲基叔丁基醚中的一种或其组合,其中特别优选乙酸乙酯。
本发明中,所述的惰性气体通常选择氮气、氩气,其中特别优选氩气。
所述米力农中间体化合物Ⅰ用于制备米力农的用途。
一种米力农中间体化合物Ⅰ用于制备米力农的方法,以米力农中间体化合物Ⅰ与α-氰基乙酰胺反应,得米力农,其合成路线如下:
所述米力农中间体化合物Ⅰ用于制备米力农的方法,具体包括如下步骤:室温下,将米力农中间体化合物Ⅰ、α-氰基乙酰胺加入有机溶剂中,搅拌均匀,在碱性环境下,控温反应,反应结束,反应液降至室温后,经析晶、过滤、干燥得米力农。
优选地,所述的米力农中间体化合物Ⅰ与α-氰基乙酰胺的投料摩尔比为1:1.1~1.7,其中特别优选1:1.4。
优选地,所述的有机溶剂为甲醇、乙醇、异丙醇、叔丁醇中的一种或其组合,其中特别优选乙醇。
优选地,所述的调节溶液碱性环境的碱为无机碱或有机碱,无机碱为氢氧化钠、氢氧化钾、氢氧化钡中的一种或其组合,其中无机碱为碱或其水溶液;有机碱为甲醇钠、乙醇钠、异丙醇钠、叔丁醇钠中的一种或其组合;其中特别优选氢氧化钠水溶液。
优选地,所述的碱性环境pH值为12~14。
优选地,所述的控温反应为控温回流反应。
在一优选方案中,所述的析晶方法为向反应液加酸调节pH值,搅拌析晶;优选地,所述的酸为甲酸、乙酸、盐酸、氢溴酸、氢碘酸中的一种或其组合,其中特别优选乙酸;优选地,所述加酸调节pH值至6~7。
本发明的有益效果:
本发明提供了一种新的米力农中间体化合物,该化合物合成简便易控;利用该化合物制备米力农,路线操作简便,有效避免氰化钾或丙二腈剧毒品的使用,提高了操作的安全性;此路线合成的白色结晶米力农外观及纯度均达到标准;运用此路线合成米力农,优选条件下,由现有公开的米力农普遍收率70%左右提升至90%以上,大大提高了原料的利用率,节约了生产成本,更适于工业化生产。
具体实施方式
下面通过实施例来进一步说明本发明,应该正确理解的是:本发明的实施例仅仅是用于说明本发明,而不是对本发明的限制,所以,在本发明的方法前提下对本发明的简单改进均属于本发明要求保护的范围。
实验所用物料:化合物α-取代乙酰乙醛(SM-1)可购买,也可参照现有公开的技术制备;其他实验所用物料未标明来源和规格的均为市售分析纯或化学纯。
本发明采用HPLC测定米力农的纯度,色谱条件如下:
色谱柱:Agilent ZORBAX Rx-C8(4.6mm×250mm,5.0μm);
流动相:磷酸氢二钾缓冲液(2.7g K2HPO4+2.4mL三乙胺+800mL水,用H3PO4调节pH至7.5)-乙腈(80:20);
柱温:30℃;
检测波长:220nm;
流速:1.0mL/min;
进样量:20μL。
以下各实施例中,未详细描述的各种过程和方法是本领域中公知的常规方法。
本发明米力农中间体化合物Ⅰ结构确认:
化合物IV的高分辨质谱:ESI-HRMS:m/z=164.0712[M+H]+;
1H-NMR(400MHz,DMSO-d6):9.72(d,J=8.0Hz,1H),8.36(d,J=7.6Hz,2H),7.21(d,J=7.6Hz,2H),4.50(d,J=7.4Hz,1H),2.30(s,3H);
13C NMR(100MHz,DMSO-d6):δ200.3,187.8,154.1,142.1,124.2,63.6,29.5。
米力农中间体化合物Ⅰ的制备
实施例1
氩气保护,室温条件下,将Pd(PPh3)4(5.82g,5.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(33.34g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.48g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.74g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.62g,收率95.8%,纯度为99.96%。
实施例2
氩气保护,室温条件下,将Pd(PPh3)4(5.80g,5.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(33.36g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.51g,0.10mol)和4-吡啶硼酸(SM-2R=OH,12.92g,0.105mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ14.77g,收率90.6%,纯度为99.92%。
实施例3
氩气保护,室温条件下,将Pd(PPh3)4(5.83g,5.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(33.37g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.52g,0.10mol)和4-吡啶硼酸(SM-2R=OH,12.27g,0.10mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ14.07g,收率87.5%,纯度为99.86%。
实施例4
氩气保护,室温条件下,将Pd(PPh3)4(5.81g,5.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(33.34g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.48g,0.10mol)和4-吡啶硼酸(SM-2R=OH,15.98g,0.13mol)搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.49g,收率95.0%,纯度为99.87%。
实施例5
氩气保护,室温条件下,将Pd(PPh3)4(5.83g,5.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(33.35g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.50g,0.10mol)和4-吡啶硼酸(SM-2R=OH,17.22g,0.14mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.42g,收率94.6%,纯度为99.76%。
实施例6
氩气保护,室温条件下,将Pd(PPh3)4(3.48g,3.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(25.47g,0.26mol)的水(40mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.51g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.75g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ14.75g,收率90.5%,纯度为99.88%。
实施例7
氩气保护,室温条件下,将Pd(PPh3)4(3.48g,3.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(24.52g,0.25mol)的水(40mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.49g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.76g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ14.25g,收率88.4%,纯度为99.74%。
实施例8
氩气保护,室温条件下,将Pd(PPh3)4(2.88g,2.50mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(25.47g,0.26mol)的水(40mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.50g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.76g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ13.92g,收率87.6%,纯度为99.82%。
实施例9
氩气保护,室温条件下,将Pd(PPh3)4(8.06g,7.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(44.15g,0.45mol)的水(65mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.48g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.75g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.52g,收率95.2%,纯度为99.82%。
实施例10
氩气保护,室温条件下,将Pd(PPh3)4(8.05g,7.00mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(45.17g,0.46mol)的水(70mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.51g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.77g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.55g,收率95.4%,纯度为99.72%。
实施例11
氩气保护,室温条件下,将Pd(PPh3)4(8.65g,7.50mmol)加入二甲基亚砜(200mL)中,搅拌混匀后,向反应液中加入KOAc(44.16g,0.45mol)的水(65mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.47g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.76g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.49g,收率95.0%,纯度为99.75%。
实施例12
氩气保护,室温条件下,将Pd(dppf)Cl2(3.64g,5.00mmol)加入二甲基亚砜(240mL)中,搅拌混匀后,向反应液中加入KOAc(33.35g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.49g,0.10mol)和4-二乙基吡啶硼烷(SM-2R=CH2CH3,17.65g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(750mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.27g,收率93.7%,纯度为99.91%。
实施例13
氩气保护,室温条件下,将Pd(PPh3)2Cl2(3.52g,5.00mmol)加入甲苯(240mL)中,搅拌混匀后,向反应液中加入KOAc(33.35g,0.34mol)的水(50mL)溶液、α-碘代乙酰乙醛(SM-1X=I,21.28g,0.10mol)和4-二乙基吡啶硼烷(SM-2R=CH2CH3,17.64g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(720mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.35g,收率94.2%,纯度为99.89%。
实施例14
氩气保护,室温条件下,将Pd(OAc)2(PPh3)2(3.73g,5.00mmol)加入1,4-二氧六环(250mL)中,搅拌混匀后,向反应液中加入KOAc(33.35g,0.34mol)的水(50mL)溶液、α-三氟甲磺酸酯乙酰乙醛(SM-1X=TfO,23.42g,0.10mol)和4-二乙基吡啶硼烷(SM-2R=CH2CH3,17.66g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(1000mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.45g,收率94.8%,纯度为99.86%。
实施例15
氩气保护,室温条件下,将Pd(PPh3)4(5.82g,5.00mmol)加入二甲基亚砜(220mL)中,搅拌混匀后,向反应液中加入K2CO3(46.97g,0.34mol)的水(50mL)溶液、α-碘代乙酰乙醛(SM-1X=I,21.19g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.74g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(700mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.13g,收率92.8%,纯度为99.87%。
实施例16
氩气保护,室温条件下,将Pd2(dba)3(4.76g,5.00mmol)加入异丙醇(250mL)中,搅拌混匀后,向反应液中加入Na3PO4(55.75g,0.34mol)的水(50mL)溶液、α-三氟甲磺酸酯乙酰乙醛(SM-1X=TfO,23.40g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.75g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(750mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.19g,收率93.2%,纯度为99.85%。
实施例17
氩气保护,室温条件下,将Pd(PPh3)4(5.82g,5.00mmol)加入乙腈(200mL)中,搅拌混匀后,向反应液中加入Cs2CO3(97.72g,0.30mol)的水(45mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.52g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.75g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(1000mL)中,二氯甲烷(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.09g,收率92.6%,纯度为99.84%。
实施例18
氩气保护,室温条件下,将Pd(dppf)Cl2(3.66g,5.00mmol)加入纯化水(200mL)中,搅拌混匀后,向反应液中加入Na2CO3(36.04g,0.34mol)的水(50mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.52g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.77g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(600mL)中,氯仿(250mL×3)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.24g,收率93.5%,纯度为99.87%。
实施例19
氩气保护,室温条件下,将Pd(OAc)2(PPh3)2(3.75g,5.00mmol)加入N,N-二甲基甲酰胺(170mL)中,搅拌混匀后,向反应液中加入K3PO4(84.92g,0.40mol)的水(60mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.50g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.75g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(850mL)中,乙酸乙酯(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ14.96g,收率91.8%,纯度为99.81%。
实施例20
氩气保护,室温条件下,将Pd(PPh3)4(5.82g,5.00mmol)加入乙醇(200mL)中,搅拌混匀后,向反应液中加入NaOAc(34.44g,0.42mol)的水(65mL)溶液、α-溴代乙酰乙醛(SM-1X=Br,16.49g,0.10mol)和4-吡啶硼酸(SM-2R=OH,14.76g,0.12mol),搅拌回流反应,反应结束,过滤,将滤液加入纯化水(800mL)中,甲基叔丁基醚(250mL×2)提取,合并有机相,无水硫酸钠干燥,过滤,滤液减压浓缩至干后,得米力农中间体化合物Ⅰ15.37g,收率94.3%,纯度为99.92%。
米力农的制备
实施例21
室温下,将米力农中间体化合物I(16.32g,0.10mol)、α-氰基乙酰胺(11.78g,0.14mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至13,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.54g,收率92.6%,纯度为99.98%。
实施例22
室温下,将米力农中间体化合物I(16.34g,0.10mol)、α-氰基乙酰胺(9.26g,0.11mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至13,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.05g,收率90.3%,纯度为99.95%。
实施例23
室温下,将米力农中间体化合物I(16.32g,0.10mol)、α-氰基乙酰胺(8.42g,0.10mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至13,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农17.85g,收率84.6%,纯度为99.83%。
实施例24
室温下,将米力农中间体化合物I(16.31g,0.10mol)、α-氰基乙酰胺(14.28g,0.17mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至13,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.31g,收率91.5%,纯度为99.91%。
实施例25
室温下,将米力农中间体化合物I(16.33g,0.10mol)、α-氰基乙酰胺(15.14g,0.18mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至13,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.16g,收率90.8%,纯度为99.76%。
实施例26
室温下,将米力农中间体化合物I(16.30g,0.10mol)、α-氰基乙酰胺(11.77g,0.14mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至11.5,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农17.43g,收率82.6%,纯度为98.83%。
实施例27
室温下,将米力农中间体化合物I(16.32g,0.10mol)、α-氰基乙酰胺(11.75g,0.14mol)加入乙醇(120mL)中,搅拌混匀,滴加7.5mol/L氢氧化钠溶液调节pH值至13,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至5.0~5.5,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农17.26g,收率81.8%,纯度为99.78%。
实施例28
室温下,将米力农中间体化合物I(16.34g,0.10mol)、α-氰基乙酰胺(11.78g,0.14mol)加入甲醇(160mL)中,搅拌混匀,滴加7.0mol/L氢氧化钾溶液调节pH值至12,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用甲酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.29g,收率91.4%,纯度为99.93%。
实施例29
室温下,将米力农中间体化合物I(16.32g,0.10mol)、α-氰基乙酰胺(11.79g,0.14mol)加入异丙醇(100mL)中,搅拌混匀,滴加8.0mol/L氢氧化钡溶液调节pH值至14,搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用盐酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.16g,收率90.8%,纯度为99.92%。
实施例30
室温下,向乙醇(100mL)中加入乙醇钠,边加边搅拌,调节溶液pH值至13;将米力农中间体化合物I(16.33g,0.10mol)、α-氰基乙酰胺(11.76g,0.14mol)加入上述乙醇溶液后,边搅拌混匀边补加乙醇钠调节溶液pH值至13;搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用盐酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.24g,收率91.2%,纯度为99.94%。
实施例31
室温下,向甲醇(80mL)中加入甲醇钠,边加边搅拌,调节溶液pH值至12;将米力农中间体化合物I(16.33g,0.10mol)、α-氰基乙酰胺(11.79g,0.14mol)加入上述甲醇溶液后,边搅拌混匀边补加甲醇钠调节溶液pH值至12;搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用氢溴酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.07g,收率90.4%,纯度为99.93%。
实施例32
室温下,向异丙醇(80mL)中加入异丙醇钠,边加边搅拌,调节溶液pH值至13;将米力农中间体化合物I(16.30g,0.10mol)、α-氰基乙酰胺(11.77g,0.14mol)加入上述异丙醇溶液后,边搅拌混匀边补加异丙醇钠调节溶液pH值至13;搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用氢碘酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.16g,收率90.8%,纯度为99.90%。
实施例33
室温下,向叔丁醇(90mL)中加入叔丁醇钠,边加边搅拌,调节溶液pH值至12;将米力农中间体化合物I(16.31g,0.10mol)、α-氰基乙酰胺(11.78g,0.14mol)加入上述叔丁醇溶液后,边搅拌混匀边补加叔丁醇钠调节溶液pH值至12;搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.07g,收率90.4%,纯度为99.91%。
实施例34
室温下,向乙醇(120mL)中加入氢氧化钠,边加边搅拌,调节溶液pH值至14;将米力农中间体化合物I(16.33g,0.10mol)、α-氰基乙酰胺(11.77g,0.14mol)加入上述乙醇溶液后,边搅拌混匀边补加氢氧化钠调节溶液pH值至14;搅拌回流反应,TLC检测反应完全后,反应结束,反应液降至室温;反应液用乙酸调节pH值至6~7,搅拌析晶,有类白色固体析出;待析晶完毕,抽滤,滤饼真空干燥,得白色结晶米力农19.35g,收率91.7%,纯度为99.95%。
Claims (10)
3.根据权利要求2所述的米力农中间体化合物Ⅰ的制备方法,其特征在于,具体包括以下步骤:惰性气体保护,室温条件下,将催化剂加入反应溶剂中,搅拌混匀后,向反应溶剂中加入碱的水溶液、化合物SM-1和化合物SM-2,搅拌控温反应,得米力农中间体化合物Ⅰ。
4.根据权利要求3所述的米力农中间体化合物Ⅰ的制备方法,其特征在于,所述的催化剂为Pd(PPh3)4、Pd(PPh3)2Cl2、Pd(dppf)Cl2、Pd2(dba)3、Pd(OAc)2(PPh3)2中的一种或其组合。
5.根据权利要求3所述的米力农中间体化合物Ⅰ的制备方法,其特征在于,所述的反应溶剂为乙醇、异丙醇、乙腈、1,4-二氧六环、水、甲苯、N,N-二甲基甲酰胺、二甲基亚砜中的一种或其组合。
6.根据权利要求3所述的米力农中间体化合物Ⅰ的制备方法,其特征在于,所述的碱为K2CO3、Na2CO3、Cs2CO3、K3PO4、Na3PO4、NaOAc、KOAc中的一种或其组合。
7.根据权利要求3所述的米力农中间体化合物Ⅰ的制备方法,其特征在于,所述的化合物SM-1、化合物SM-2、碱、催化剂的投料摩尔比为1:1.05~1.3:2.6~4.5:0.03~0.07。
8.根据权利要求3所述的米力农中间体化合物Ⅰ的制备方法,其特征在于,所述的控温反应为控温回流反应。
9.权利要求1所述米力农中间体化合物Ⅰ用于制备米力农的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910213586.2A CN111718292B (zh) | 2019-03-20 | 2019-03-20 | 一种米力农中间体化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910213586.2A CN111718292B (zh) | 2019-03-20 | 2019-03-20 | 一种米力农中间体化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111718292A CN111718292A (zh) | 2020-09-29 |
CN111718292B true CN111718292B (zh) | 2023-05-02 |
Family
ID=72562915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910213586.2A Active CN111718292B (zh) | 2019-03-20 | 2019-03-20 | 一种米力农中间体化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111718292B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364776A (en) * | 1991-10-04 | 1994-11-15 | Merck & Co., Inc. | Method of hydroxylating 3-[3-(5-ethyl-2-methoxy-6-methylpyridyl)methyl]amino-5-ethyl-6-methyl-2(1H)-pyridinone with liver slices |
CN101143844A (zh) * | 2007-01-16 | 2008-03-19 | 张刘森 | 乳酸米力农的制备方法 |
CN101157590A (zh) * | 2007-11-23 | 2008-04-09 | 武汉大学 | α-芳基羰基化合物的制备方法 |
CN104387320A (zh) * | 2014-09-28 | 2015-03-04 | 湖州展望药业有限公司 | 一种高纯度米力农的制备方法 |
CN105530814A (zh) * | 2013-07-09 | 2016-04-27 | 拜耳作物科学股份公司 | 经选择的吡啶酮甲酰胺或其盐作为活性物质抵抗植物非生物胁迫的用途 |
CN107698501A (zh) * | 2017-10-25 | 2018-02-16 | 遵义医学院 | 5,6‑二甲基‑2‑羟基烟酸的制备工艺 |
-
2019
- 2019-03-20 CN CN201910213586.2A patent/CN111718292B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364776A (en) * | 1991-10-04 | 1994-11-15 | Merck & Co., Inc. | Method of hydroxylating 3-[3-(5-ethyl-2-methoxy-6-methylpyridyl)methyl]amino-5-ethyl-6-methyl-2(1H)-pyridinone with liver slices |
CN101143844A (zh) * | 2007-01-16 | 2008-03-19 | 张刘森 | 乳酸米力农的制备方法 |
CN101157590A (zh) * | 2007-11-23 | 2008-04-09 | 武汉大学 | α-芳基羰基化合物的制备方法 |
CN105530814A (zh) * | 2013-07-09 | 2016-04-27 | 拜耳作物科学股份公司 | 经选择的吡啶酮甲酰胺或其盐作为活性物质抵抗植物非生物胁迫的用途 |
CN104387320A (zh) * | 2014-09-28 | 2015-03-04 | 湖州展望药业有限公司 | 一种高纯度米力农的制备方法 |
CN107698501A (zh) * | 2017-10-25 | 2018-02-16 | 遵义医学院 | 5,6‑二甲基‑2‑羟基烟酸的制备工艺 |
Non-Patent Citations (4)
Title |
---|
A convenient synthesis of nicotinate esters from 3-cyanopyridones;John B. Paine;《J. Heterocyclic Chem.》;19870430;第24卷;第351-355页 * |
Ni-Catalyzed Mild Arylation of a-Halocarbonyl Compounds with Arylboronic Acids;Chao Liu等;《Org. Lett.》;20071204;第9卷(第26期);第5601-5604页 * |
Pd-catalyzed synthesis of arylacetic acid derivatives from boronic acids;Lukas J. Goossen;《Chem. Commun.》;20010321;第669-670页 * |
何仁等编著.Suzuki偶联反应.《金属有机化学》.上海:华东理工大学出版社,2007,第294-300页. * |
Also Published As
Publication number | Publication date |
---|---|
CN111718292A (zh) | 2020-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111233930B (zh) | 一种瑞德西韦的制备方法 | |
CN110606842B (zh) | 吡啶胺基嘧啶衍生物的制备方法及其中间体 | |
CN113214223B (zh) | 一种富马酸伏诺拉生杂质的制备方法 | |
KR20230026411A (ko) | 방향족 에터 화합물의 제조 방법 | |
CN111718292B (zh) | 一种米力农中间体化合物 | |
JP2023525732A (ja) | 抗腫瘍化合物の合成方法及びその中間体 | |
CN111718295B (zh) | 一种高纯度米力农的制备方法 | |
CN109776407B (zh) | 一种2-甲基-4-羟甲基喹啉及其衍生物的制备方法 | |
CN109824579B (zh) | 一种(s)-苯基(吡啶-2-基)甲醇衍生物的制备方法 | |
CN114213343B (zh) | 一种赛乐西帕中间体的制备及其纯化方法 | |
CN113121438A (zh) | 一种异喹啉酮类化合物的制备方法 | |
CN114369085B (zh) | 盐酸Asciminib的制备方法 | |
CN111377858B (zh) | 一种米力农的制备方法 | |
CN112028874B (zh) | 艾立替尼的合成方法 | |
CN115141180A (zh) | 一种鲁索替尼中间体的制备方法 | |
CN113493410B (zh) | 一种米力农的制备工艺 | |
CN115448848A (zh) | 一种抗真菌化合物制备方法 | |
CN113372281A (zh) | 一种特硝唑的合成方法 | |
CN112552345A (zh) | 一种nk-1受体拮抗剂的制备方法 | |
CN111377857B (zh) | 一种米力农的合成方法 | |
CN112480172A (zh) | 硼烷-吡啶络合物在制备药物化合物中的用途 | |
CN115785057B (zh) | 一种替卡格雷中间化合物及其盐的制备方法 | |
CN113493406B (zh) | 一种米力农中间体的制备方法 | |
CN113754597B (zh) | 一种含直链烯烃的二苯甲基哌嗪类化合物及其制备方法 | |
CN113045575B (zh) | 一种化合物的制备方法及其中间体和中间体的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |